T\u00fcrkiye\u2019de ve d\u00fcnyada tedavisi zor ve agresif seyreden tiroit kanserleri i\u00e7in umut verici bir geli\u015fme ya\u015fand\u0131. The University of Texas MD Anderson Cancer Center ara\u015ft\u0131rmac\u0131lar\u0131 taraf\u0131ndan geli\u015ftirilen yeni nesil bir Chimeric Antigen Receptor (CAR) T h\u00fccre terapisi olan AIC100, ilk kez insanlarda yap\u0131lan Faz I klinik \u00e7al\u0131\u015fmada etkileyici erken sonu\u00e7lar g\u00f6sterdi. \u00d6zellikle anaplastik tiroit kanseri (ATC) ve iyi diferansiye olmayan tiroit kanseri (PDTC) gibi zorlu alt tiplerde denenmeye ba\u015flayan bu imm\u00fcnoterapi y\u00f6ntemi, yeni tedavi yakla\u015f\u0131mlar\u0131na olan inanc\u0131 art\u0131rd\u0131.<\/p>\n
Tiroit kanserleri aras\u0131nda en k\u00f6t\u00fc prognoza sahip olan ATC ve PDTC, mevcut standart tedavilere diren\u00e7li ve hastalar\u0131n ya\u015fam s\u00fcresi genellikle aylarla s\u0131n\u0131rl\u0131d\u0131r. Standart kemoterapi, radyoterapi ve cerrahi gibi y\u00f6ntemler \u00e7o\u011fu hastada etkin olamad\u0131\u011f\u0131 i\u00e7in yeni, \u00f6zelle\u015fmi\u015f terapilere ihtiya\u00e7 duyulmaktad\u0131r. AIC100, bu ba\u011flamda ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin T lenfositlerini genetik olarak programlayarak, hastal\u0131kl\u0131 tiroit h\u00fccrelerinin h\u00fccre y\u00fczeyinde bulunan intersel\u00fcler adezyon molek\u00fcl 1 (ICAM-1) proteinini hedef alacak \u015fekilde tasarlanm\u0131\u015ft\u0131r. T\u00fcm\u00f6r h\u00fccrelerine \u00f6zg\u00fcn bu hedefleme, temelde tedavi etkinli\u011fini art\u0131r\u0131rken yan etkileri en aza indirmeyi ama\u00e7lamaktad\u0131r.<\/p>\n
AIC100 konstr\u00fcksiyonu, CAR T h\u00fccre terapilerinde \u00fc\u00e7\u00fcnc\u00fc nesil bir tasar\u0131ma sahiptir; bu, daha \u00f6nceki nesillere k\u0131yasla tedavinin etkinli\u011fini art\u0131r\u0131p, solid t\u00fcm\u00f6rlerin mikro ortam\u0131ndaki zorlu ko\u015fullara kar\u015f\u0131 dayan\u0131kl\u0131l\u0131\u011f\u0131n\u0131 artt\u0131rmak \u00fczere geli\u015ftirilmi\u015ftir. Ayr\u0131ca, t\u00fcm\u00f6rlerle etkile\u015fimi ve da\u011f\u0131l\u0131m\u0131 takip etmek amac\u0131yla CAR T h\u00fccrelerine somatostatin resept\u00f6r 2 proteini eklenmi\u015ftir. Bu modifikasyon, pozitron emisyon tomografisi (PET) ile yap\u0131lan g\u00f6r\u00fcnt\u00fcleme y\u00f6ntemine olanak tan\u0131yarak, gebelikten ba\u011f\u0131ms\u0131z olarak tedavinin dinamik takibini sa\u011flar. B\u00f6ylece tedavi s\u0131ras\u0131nda h\u00fccrelerin doku i\u00e7indeki hareketi, tutunmas\u0131 ve etkinli\u011fi ger\u00e7e\u011fe en yak\u0131n \u015fekilde g\u00f6r\u00fclebilmektedir.<\/p>\n
\u00c7ok merkezli bu Faz I denemede 24 yeti\u015fkin hastaya, yeni tan\u0131 konmu\u015f veya relaps\/refrakter ATC ya da PDTC tan\u0131s\u0131 ile ba\u015fvuruldu. Hastalar\u0131n bir\u00e7o\u011fu, ortalama iki farkl\u0131 standart tedavi rejimini denemi\u015f ve ba\u015far\u0131l\u0131 olmam\u0131\u015f durumdayd\u0131. Deneme, kademeli doz art\u0131\u015f\u0131 \u015feklinde dizayn edilerek, \u00fc\u00e7 farkl\u0131 ba\u015flang\u0131\u00e7 dozu denenmi\u015f ve her doz sonras\u0131 l\u00f6kodepleksiyon (ba\u011f\u0131\u015f\u0131kl\u0131k sistemi bask\u0131lay\u0131c\u0131 kemoterapi) uygulanm\u0131\u015ft\u0131r. Bu prosed\u00fcr, hastalar\u0131n kendi diren\u00e7 g\u00f6sterici ba\u011f\u0131\u015f\u0131kl\u0131k h\u00fccrelerini azaltarak CAR T h\u00fccrelerinin v\u00fccuda daha iyi tutunmas\u0131n\u0131 ve \u00e7o\u011falmas\u0131n\u0131 hedefler. Denemede toplam 15 hastaya AIC100 verilmi\u015f olup \u00f6zellikle ikinci ve \u00fc\u00e7\u00fcnc\u00fc doz kademelerinde \u00f6nemli klinik yan\u0131tlar g\u00f6zlemlenmi\u015ftir.<\/p>\n
\u0130kinci ve \u00fc\u00e7\u00fcnc\u00fc doz kademelerinde tedavi alan d\u00f6rt ATC hastas\u0131nda objektif yan\u0131t oran\u0131 y\u00fczde 50 olarak kaydedilmi\u015ftir. Bu d\u00f6rt hastadan biri komple remisyonda olup, di\u011feri ise k\u0131smi yan\u0131t vermi\u015ftir. Bu yan\u0131t oran\u0131, b\u00f6ylesine agresif seyreden ve genellikle tedaviye diren\u00e7li olan bir hasta grubunda ilk kez g\u00f6r\u00fclmekte olan bir ba\u015far\u0131d\u0131r. Ayr\u0131ca, be\u015f PDTC hastas\u0131ndan \u00fc\u00e7\u00fc hastal\u0131k stabilizasyonu sa\u011flam\u0131\u015f ve bu tip tiroit kanserlerinin de bu yeni imm\u00fcnoterapik yakla\u015f\u0131ma uygun olabilece\u011fi fikrini desteklemi\u015ftir.<\/p>\n
G\u00fcvenlik a\u00e7\u0131s\u0131ndan da ilk \u00fc\u00e7 doz kademesinde ciddi ve tedaviye k\u0131s\u0131tlay\u0131c\u0131 yan etkiler g\u00f6r\u00fclmemi\u015ftir. Kar\u015f\u0131la\u015f\u0131lan yan etkiler genel olarak hafif ile orta d\u00fczeyde sitokin sal\u0131n\u0131m sendromu (CRS) olarak raporlanm\u0131\u015f, bu durum ise mevcut CAR T protokollerinde s\u0131k\u00e7a rastlanan, ancak kontroll\u00fc ve ge\u00e7ici bir s\u00fcre\u00e7 olmu\u015ftur. Bunun yan\u0131 s\u0131ra, sinir sistemi \u00fczerinde olumsuz etkileri olan immune effector cell-associated neurotoxicity syndrome (ICANS) bildirilmemi\u015ftir ki bu, CAR T tedavilerinde hastalar i\u00e7in \u00f6nemli bir avantaj olarak de\u011ferlendirilmi\u015ftir. Ancak d\u00f6rd\u00fcnc\u00fc doza \u00e7\u0131k\u0131ld\u0131\u011f\u0131nda iki hastada ciddi (grade 3) pn\u00f6moni geli\u015fmesi, doz optimizasyonunun kritik \u00f6nemini ortaya koymu\u015ftur.<\/p>\n
Elde edilen g\u00fcvenlik ve etkinlik verileri \u0131\u015f\u0131\u011f\u0131nda ara\u015ft\u0131rmac\u0131lar, Faz II \u00e7al\u0131\u015fmalar\u0131 i\u00e7in \u00fc\u00e7\u00fcnc\u00fc doz kademesini \u00f6nerilen doz olarak belirlemi\u015ftir. Bu geli\u015fme, solid t\u00fcm\u00f6rlerle m\u00fccadelede uzun y\u0131llard\u0131r devam eden \u201eCAR T\u2019nin etkinlik g\u00f6sterememesi\u201d sorununa kar\u015f\u0131 \u00f6nemli bir ba\u015far\u0131 olarak kabul edilmektedir. T\u00fcm\u00f6r heterojenli\u011fi, imm\u00fcn bask\u0131lay\u0131c\u0131 mikro \u00e7evre ve T h\u00fccrelerinin t\u00fcm\u00f6r dokusuna ula\u015fmas\u0131ndaki zorluklar gibi engeller, bu yeni yap\u0131sal \u00f6zelli\u011fe sahip CAR T h\u00fccreleriyle a\u015f\u0131labilmi\u015ftir.<\/p>\n
AIC100\u2019\u00fcn ayn\u0131 zamanda in vivo ger\u00e7ek zamanl\u0131 PET g\u00f6r\u00fcnt\u00fcleme ile izlenebilmesi, tedavinin kinetik ve persistanl\u0131k \u00f6zelliklerini de\u011ferlendirmede \u00f6nemli bir avantaj yaratmaktad\u0131r. Bu teknoloji, CAR T h\u00fccrelerinin canl\u0131 hastalardaki davran\u0131\u015f\u0131 hakk\u0131nda bilgi vererek tedavinin etkinli\u011fi ve direnci konusunda erken uyar\u0131lar sa\u011flar. B\u00f6ylece, tedavi protokol\u00fcnde dinamik d\u00fczenlemeler yap\u0131larak, olas\u0131 n\u00fcks ya da tedaviye diren\u00e7li klinik durumlar daha etkin \u015fekilde y\u00f6netilebilir.<\/p>\n
Ara\u015ft\u0131rman\u0131n ba\u015f\u0131ndaki isimlerden biri olan Dr. Samer Srour, elde edilen bu remisyonlar\u0131n bu klinik zorluktaki hastalar i\u00e7in adeta bir d\u00f6n\u00fcm noktas\u0131 oldu\u011funu vurgulam\u0131\u015ft\u0131r. Hastal\u0131k kontrol s\u00fcresi ve tam yan\u0131t elde edilen vakalar\u0131n bulunmas\u0131, bu terapinin tiroit kanserinde standard tedavi yakla\u015f\u0131mlar\u0131na k\u0131yasla hayatta kalma oranlar\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde y\u00fckseltebilece\u011fi anlam\u0131na gelmektedir. Bu durum, klinik prati\u011fe anlaml\u0131 bir de\u011fi\u015fim getirebilir ve uzun vadede tiroit kanserlerinin y\u00f6netiminde yeni standartlar belirleyebilir.<\/p>\n
Bu Faz I klinik \u00e7al\u0131\u015fma, AffyImmune Therapeutics taraf\u0131ndan finanse edilmi\u015f olup, akademi ve end\u00fcstri i\u015f birli\u011finin yeni nesil kanser tedavilerinin geli\u015ftirilmesinde ne denli kritik oldu\u011funu ortaya koymu\u015ftur. Ara\u015ft\u0131rma ekibi, \u00f6n\u00fcm\u00fczdeki d\u00f6nemde daha b\u00fcy\u00fck \u00f6l\u00e7ekli \u00e7al\u0131\u015fmalarla tedavinin uzun d\u00f6nem etkinli\u011fi, g\u00fcvenli\u011fi ve optimal dozaj\u0131n\u0131n tespitini hedeflemektedir. Onkoloji camias\u0131 da bu yeni tedavi yakla\u015f\u0131m\u0131n\u0131n getirece\u011fi potansiyel de\u011fi\u015fiklikleri merakla beklemektedir.<\/p>\n
\u00d6zetle, AIC100 yap\u0131land\u0131rmas\u0131 ve erken Faz I denemede elde edilen g\u00fcvenlik ve etkinlik sonu\u00e7lar\u0131, solid t\u00fcm\u00f6rlerde CAR T h\u00fccre terapilerinin \u00f6n\u00fcndeki \u00f6nemli engellerin a\u015f\u0131labilece\u011fine dair g\u00fc\u00e7l\u00fc bir kan\u0131t olarak \u00f6ne \u00e7\u0131km\u0131\u015ft\u0131r. \u00d6zellikle agresif tiroit kanserleri gibi tedavi se\u00e7eneklerinin olduk\u00e7a s\u0131n\u0131rl\u0131 oldu\u011fu alanlarda, ki\u015fiselle\u015ftirilmi\u015f imm\u00fcnoterapiler hastal\u0131k y\u00f6netiminde bir paradigma kaymas\u0131 yaratabilir. Gelecekte bu t\u00fcr yakla\u015f\u0131mlar\u0131n yayg\u0131nla\u015fmas\u0131, bu \u00f6l\u00fcmc\u00fcl hastal\u0131klar\u0131n kontrol alt\u0131na al\u0131nmas\u0131 veya tamamen ortadan kald\u0131r\u0131lmas\u0131 ad\u0131na b\u00fcy\u00fck bir ad\u0131m olabilir.<\/p>\n
—<\/p>\n
**Ara\u015ft\u0131rma Konusu**: CAR T h\u00fccre terapisi ile diren\u00e7li agresif tiroit kanserlerinde ICAM-1 hedeflemesi
\n**Makale Ba\u015fl\u0131\u011f\u0131**: Novel CAR T Cell Therapy AIC100 Shows Promising Early Results in Aggressive Thyroid Cancers
\n**Haberin Yay\u0131n Tarihi**: 29 Nisan 2025
\n**Web References**:
\nhttps:\/\/www.mdanderson.org\/treatment-options\/car-t-cell-therapy.html
\nhttps:\/\/www.mdanderson.org\/cancer-types\/thyroid-cancer.html
\nhttps:\/\/faculty.mdanderson.org\/profiles\/samer_srour.html
\nhttps:\/\/www.abstractsonline.com\/pp8\/#!\/20273\/presentation\/10430
\nhttps:\/\/MDAnderson.org\/AACR
\n**Resim Credits**: The University of Texas MD Anderson Cancer Center
\n**Anahtar Kelimeler**: Kanser tedavileri, H\u00fccre terapileri, Tiroit kanseri, T h\u00fccresi yan\u0131tlar\u0131, Klinik ara\u015ft\u0131rmalar, T lenfositleri, Tiroit hastal\u0131klar\u0131, Gen hedefleme, Solid t\u00fcm\u00f6rler, Hedef proteinler, Kanser ara\u015ft\u0131rmalar\u0131, Kanser n\u00fcks\u00fc, T\u00fcm\u00f6r h\u00fccreleri, Hastal\u0131k kontrol\u00fc<\/p>\n","protected":false},"excerpt":{"rendered":"
T\u00fcrkiye\u2019de ve d\u00fcnyada tedavisi zor ve agresif seyreden tiroit kanserleri i\u00e7in umut verici bir geli\u015fme ya\u015fand\u0131. The University of Texas MD Anderson Cancer Center ara\u015ft\u0131rmac\u0131lar\u0131 taraf\u0131ndan geli\u015ftirilen yeni nesil bir Chimeric Antigen Receptor (CAR) T h\u00fccre terapisi olan AIC100, ilk kez insanlarda yap\u0131lan Faz I klinik \u00e7al\u0131\u015fmada etkileyici erken sonu\u00e7lar g\u00f6sterdi. \u00d6zellikle anaplastik tiroit kanseri…<\/p>\n","protected":false},"author":1,"featured_media":4273,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[4182,4184,4181,4180,4183],"tmauthors":[],"class_list":{"0":"post-4272","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-aic100-immunoterapi-klinik-calismasi","9":"tag-car-t-hucre-tedavisinde-pet-goruntuleme","10":"tag-car-t-hucre-terapisi-anaplastik-tiroit-kanseri","11":"tag-ileri-tiroit-kanseri-tedavisi","12":"tag-tiroit-kanserinde-hedefe-yonelik-tedavi"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/04\/Ileri-Tiroid-Kanserinde-Yenilikci-CAR-T-Hucre-Tedavisi-1745946867.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/4272","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=4272"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/4272\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/4273"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=4272"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=4272"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=4272"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=4272"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}